Auris Medical Holding Ag (EARS) 4.65 $EARS Midday

New Post Public Reply Private Reply Replies (0) Message Board

Apr 22, 2015 at 10:04 PM

Auris Medical Holding Ag (EARS) 4.65 $EARS

Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 11:45AM CDT

AEC: 28.49 (+4.01), SMCI: 31.90 (-2.91), CAMP: 20.87 (+4.19), GEVO: 2.79 (+0.78), DSKX: 1.64 (+0.30), CCIH: 14.86 (+2.54), ENZN: 1.70 (+0.20), NRP: 5.54 (-1.38), PARN: 4.19 (-0.30), GBSN: 4.98 (+1.44), AMSC: 10.40 (+1.20), PW: 6.33 (-2.95), EARS: 4.65 (-0.75), EMMS: 1.61 (-0.24), COOL: 1.40 (-0.21), LOOK: 1.75 (-0.51), ONVO: 5.14 (+0.67), HMNY: 2.90 (-0.63), PKT: 11.42 (+1.91), ZHNE: 1.89 (+0.36)

Auris Medical off 17% on modest volume
Seeking Alpha - at Seeking Alpha - Wed Apr 22, 10:44AM CDT

EARS: 4.65 (-0.75)

Auris Medical Announces Publications Related to AM-101 in Peer-Reviewed Scientific and Medical Journals
GlobeNewswire - Mon Apr 20, 3:10PM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced publications related to AM-101, the Company's lead product candidate for the treatment of acute inner ear tinnitus, in two peer-reviewed specialist journals. "We are very pleased to see these important additional pre-clinical and clinical data published on our AM-101 program", commented Thomas Meyer, Auris Medical's founder, Chairman and CEO. "They add further to our understanding of the pathogenesis of inner ear tinnitus as well as AM-101's therapeutic effects and potential clinical use."
EARS: 4.65 (-0.75)

Auris Medical to Propose Election of Two New Board Members at Forthcoming Annual General Meeting
GlobeNewswire - Mon Mar 30, 5:12PM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedi-cated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that its Board of Directors will propose the election of two new members of the Board of Directors at its forthcoming Annual General Meeting:
EARS: 4.65 (-0.75)

LifeSci Capital Initiates Coverage of Auris Medical
ACCESSWIRE - Mon Mar 23, 8:02AM CDT
Focused on Developing First-in-Class Therapeutics for Inner Ear Disorders
EARS: 4.65 (-0.75)

Zacks Rank #1 Additions for Friday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:30AM CDT
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for Friday
EVOL: 9.42 (-0.19), FLML: 15.84 (-0.33), EARS: 4.65 (-0.75), FICO: 92.00 (-0.15), CTRN: 24.27 (+0.16)

Genocea Biosciences, Inc. (GNCA) in Focus: Stock Rises 5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:21AM CDT
Genocea Biosciences, Inc. (GNCA) was a big mover last session, as the company saw its shares rise over 5% on the day.
EARS: 4.65 (-0.75), GNCA: 12.48 (-0.23)

Bellicum Pharmaceuticals, Inc. (BLCM) in Focus: Stock Jumps 6.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 20, 8:18AM CDT
Bellicum Pharmaceuticals, Inc. (BLCM) was a big mover last session, as the company saw its shares rise over 6% on the day.
EARS: 4.65 (-0.75), BLCM: 28.55 (+2.59)

Auris Medical Holding's (EARS) CEO Thomas Meyer on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Thu Mar 19, 1:50PM CDT

EARS: 4.65 (-0.75)

Auris Medical Q4 and FY14 results
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 8:54AM CDT

EARS: 4.65 (-0.75)

Auris reports 4Q loss
Automated Insights - Thu Mar 19, 6:39AM CDT
4001 BASEL, Switzerland (AP) _ Auris Medical Holding AG (EARS) on Thursday reported a loss of $4 million in its fourth quarter.
EARS: 4.65 (-0.75)

Auris Medical beats by $0.18
Seeking Alpha - at Seeking Alpha - Thu Mar 19, 6:12AM CDT

EARS: 4.65 (-0.75)

Auris Medical Holding AG Reports Fourth Quarter and Full Year 2014 Financial Results and Provides Business Update
GlobeNewswire - Thu Mar 19, 6:08AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today provided an update on the Company's business and announced financial results for the fourth quarter and financial year ended December 31, 2014.
EARS: 4.65 (-0.75)

Tinnitus Therapeutic Development and Pipeline Market Review H1 2015 Available at RnRMarketResearch.com
PRWeb - Tue Mar 17, 11:30AM CDT
The report "Tinnitus - Pipeline Review, H1 2015" provides comparative analysis on the therapeutic development for Tinnitus. Tinnitus is the medical term for "hearing" noises in your ears when there is no outside source of the sounds. It can make verbal communication impossible and can cause depression. Depending on the type of tinnitus, symptoms will tend to come and go over time. Stress level, diet, and exposure to noise can worsen tinnitus. The report strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Complete report with TOC is available @ http://www.rnrmarketresearch.com/tinnitus-pip...eport.html .
FLXN: 18.77 (-0.78), EARS: 4.65 (-0.75), OTIC: 32.83 (unch)

Auris Medical to Announce Fourth Quarter and Full Year 2014 Financial Results and Host Conference Call on Thursday, March 19, 2015
GlobeNewswire - Mon Mar 16, 7:46AM CDT
Auris Medical Holding AG (Nasdaq:EARS) today announced that it will release its financial results for the fourth quarter and full year 2014, on Thursday, March 19, 2015. Following the announcement, Auris Medical's management will host a live conference call and webcast at 8:00 a.m. Eastern Time (1:00 p.m. Central European Time) to discuss Auris Medical's financial results for the fourth quarter and full year 2014 and provide a general business update.
EARS: 4.65 (-0.75)

Auris Medical Announces Recently Granted Patent in India for the Treatment of Tinnitus
GlobeNewswire - Fri Mar 13, 6:05AM CDT
Auris Medical Holding AG (Nasdaq:EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it has recently been granted a patent by the Indian patent office covering the use of its investigational tinnitus treatment AM-101. India patent No. 264994 describes methods for the treatment of tinnitus induced by cochlear excitotoxicity, and notably the use of Ketamine and related compounds for that purpose.
EARS: 4.65 (-0.75)

Auris Medical to Host Key Opinion Leader Meeting on Tinnitus Treatments on March 13 in New York City
GlobeNewswire - Wed Mar 11, 6:06AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced that it will host a Key Opinion Leader breakfast focused on current advances in tinnitus treatments. The event and live webcast will take place on Friday, March 13 from 8:00am-9:30am Eastern Time in New York City.
EARS: 4.65 (-0.75)

Auris Medical Announces Completion of Interim Analysis in Post-Acute Tinnitus Stratum of TACTT3 Trial with AM-101
GlobeNewswire - Tue Mar 10, 7:23AM CDT
Auris Medical Holding AG (NASDAQ: EARS), a clinical-stage company dedicated to developing therapeutics that address important unmet medical needs in otolaryngology, today announced the completion of the planned interim analysis in the post-acute tinnitus stratum of the TACTT3 trial ("Stratum B"

with AM-101 and that enrollment could continue since the pre-specified futility threshold was not reached. Based on recommendations by the Independent Data Review Committee, the inclusion criteria will be adapted in order to focus on the early post-acute stage where higher levels of activity were observed than at the later stage. Accordingly, Stratum B will continue to enroll patients with tinnitus having started between 3 and 6 months prior and stop enrollment of patients with onset 6 to 12 months prior. The TACTT2 trial and Stratum A of TACTT3, which enroll patients with tinnitus up to 3 months from onset and were not part of the interim analysis, will continue unchanged.
EARS: 4.65 (-0.75)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Servier's Data on Tovorafenib Shows Promise in pLGG

New Light on a Critical Challenge Talk about a fight in the dark. Pediatric low-grade glioma (pLGG) is a menace that families dread, an uphill battle with odds that feel relentless. Enter Servier and its four-year updated data on OJEMDA® (tovorafenib), a beacon of hope for kids battling these tricky brain tumors. Results, presented at the SNO meeting, are fresh off the...

YSTUDIO's Pens: A Nod to the Power of Writing

Slow Down, Write On: A New Era for Stationery In a world where sentiments zip around with a swipe, here we find YSTUDIO tapping into something analog and profound. Their latest offerings—a 'Brand Day Gift Box' and the 'Inner Universe' pen series—are more than just high-end stationery. They’re an invitation to reconnect with the written word, a gesture to slow our...

CARsgen's CAR-T Breakthrough on China's Insurance List

A Game Changer for CAR-T Therapies There's a breeze of optimism blowing from Shanghai these days—a rare sensation in this market of endless skirmishes. CARsgen Therapeutics Holdings Limited, a company entrenched in the development of cutting-edge CAR T-cell therapies, just notched a victory. They've announced that their CAR T-cell therapy product, satricabtagene...

HONGQI's EHS4 Launch in Europe: Bridging East and West

Revving Up a New Chapter: HONGQI in Venice There's a new player in the European automotive scene, and it's rolling in with more style than a Venetian gondola. HONGQI, a name that's been turning gears in China since '58, is packing its suitcases full of Eastern elegance and landing straight in Venice with the all-electric EHS4. On November 16, the brand is set to unveil...

Novo's CagriSema Trial Shows Promising Obesity Results

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Lilly's Obesity Breakthroughs: A Step Beyond the Scale

Pushing the Boundaries of Obesity Treatment Alright, let's cut through the noise and get to what really matters here. Eli Lilly is taking on obesity treatment like it's Clash of the Titans at this year's ObesityWeek 2026 in Washington, D.C. Forget just dropping pounds—Lilly wants to reshape how we think about obesity entirely. They're not just leaning into the scale,...

Shenzhen's Vision Unveiled: APEC 2026 Promo Debut

Shenzhen's Spotlight Moment at APEC 2026 When Shenzhen announced its promotional video for the 2026 APEC Economic Leaders' Meeting, it wasn't just about standard tourism glitz. This was a show of force, a bold step onto the main stage of global politics and economics. The video's launch wasn’t merely an audio-visual delight—it staked a claim in shaping the future...

PASCAL's Holiday Gift Edit: Timeless Watches Shine

Fresh Sparkle for the Holidays Well, here we are again, staring down the barrel of another holiday season. And what do you know, PASCAL is out with its 2026 Holiday Gift Edit, like clockwork. This is the kind of stuff they’re good at—capturing a moment, slapping some color on it, and calling it a game-changer. Launching on November 14, this edit nods to their Timeless...

Luvme Hair Offers Wig Variety for Winter Fashion

Adding Flair to Winter Looks A style kick-off from the fashion world: Luvme Hair is flipping the table on winter wardrobes with a new collection of wigs. As the weather ramps up the need for thick coats and cumbersome layers, these long hairstyles offer a little extra swing, bringing dimension into the mix. Fancy a change from traditional winter hibernation? Here’s what...

WHO and RCSI Bahrain Join Forces on Health Initiatives

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...